Clinical Trials on Adrenal Cortex Carcinoma

Total 33642 results

Spanish Oncology Genito-Urinary Group
GlaxoSmithKline

Completed

Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Spain
Astellas Pharma Global Development, Inc.

Completed

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Canada
UNICANCER
Bristol-Myers Squibb

Completed

Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen (NIVOREN)

Metastatic Renal Cell Carcinoma

France
Takeda

Completed

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Japan
Assistance Publique - Hôpitaux de Paris
Pfizer

Completed

Clinical Trial to Assess the Importance of Nephrectomy (CARMENA)

Metastatic Renal Cell Carcinoma

France
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb (PIPELINE)

Metastatic Renal Cell Carcinoma
Amgen

Completed

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

Advanced Renal Cell Carcinoma
NewLink Genetics Corporation

Completed

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Metastatic Renal Cell Carcinoma

Korea, Republic of, United States
Inge Marie Svane

Unknown

TIL Therapy for Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

Denmark
Eli Lilly and Company

Completed

A Study for Participants With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

Austria, France, Italy, Poland
Peking University

Withdrawn

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Metastatic Renal Cell Carcinoma
Spanish Oncology Genito-Urinary Group

Completed

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib (Spazo-2)

Metastatic Renal Cell Carcinoma

Spain
Immatics Biotechnologies GmbH

Completed

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, France, Romania, United Kingdom, Italy, Russian Federation, Poland, Germany, Hungary, Netherlands, Norway
National Cancer Institute (NCI)

Completed

Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Metastatic Renal Cell Carcinoma

United States, Peru
Peking University Cancer Hospital & Institute

Unknown

A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.

Metastatic Renal Cell Carcinoma

China
Imperial College Healthcare NHS Trust

Withdrawn

Functional Imaging in the Assessment of mRCC Response to Sunitinib

Metastatic Renal Cell Carcinoma

United Kingdom
Mendus

Completed

A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma

Sweden
Centro di Riferimento Oncologico - Aviano

Terminated

Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC)

Metastatic Renal Cell Carcinoma

Italy
Amgen

Completed

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma
Spanish Oncology Genito-Urinary Group

Completed

Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy (SOGUG/0107)

Carcinoma Renal Cells

Spain
University of Aarhus
Danish Renal Cancer Study Group

Unknown

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma

Denmark
Netherlands Working Group on Immunotherapy of Oncology

Completed

Rotating Pazopanib and Everolimus to Avoid Resistance (ROPETAR)

Clear Cell Renal Carcinoma

Netherlands
University of Chicago

Terminated

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
Centre Leon Berard

Completed

Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma (TORAVA)

Metastatic Renal Cell Carcinoma

France
Pfizer

Completed

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Metastatic Renal Cell Carcinoma

Czech Republic
Bayer

Completed

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Belgium
Tianjin Medical University Second Hospital

Not yet recruiting

A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer (SAARCC)

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma

China
Columbia University
Novartis

Recruiting

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1)

Carcinoma, Renal Cell

United States
Pfizer
Analysis Group; IMDC group

Completed

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Metastatic Renal Cell Carcinoma (mRCC)

Canada
Pfizer

Completed

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (ADONIS)

Metastatic Renal Cell Carcinoma (mRCC)

Spain, Italy, Belgium, France, United Kingdom, Austria, Greece, Netherlands
Calithera Biosciences, Inc

Completed

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) (ENTRATA)

Clear Cell Renal Cell Carcinoma

United States
Arrowhead Pharmaceuticals

Completed

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Advanced or Metastatic Renal Cell Carcinoma

Japan
Pfizer

Completed

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

Metastatic Renal Cell Carcinoma ( mRCC)

Ecuador, Argentina, Brazil, Colombia
Radboud University Medical Center
Dutch Cancer Society

Completed

IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC) (IMPACT-RCC)

Kidney Neoplasms | Clear-cell Metastatic Renal Cell Carcinoma

Netherlands
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Renal Cell Carcinoma | Clear-cell Metastatic Renal Cell Carcinoma

United States, Canada
UNICANCER

Completed

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Kidney Cancer

France
Herlev and Gentofte Hospital

Unknown

Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma (INDIGO)

Urologic Neoplasms | Urogenital Neoplasms | Metastatic Renal Cell Carcinoma | Kidney Neoplasm

Denmark
Tianjin Medical University Cancer Institute and...

Unknown

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma

China
University Hospital, Bordeaux

Completed

Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma (ChemoRenCan)

Kidney Neoplasms | Kidney Diseases | Carcinoma | Carcinoma Renal Cell | Chemokines

France
University of California, San Diego
The Cleveland Clinic

Unknown

Prior Axitinib as a Determinant of Outcome of Renal Surgery (PADRES)

Clear Cell Renal Cell Carcinoma

United States
Argos Therapeutics

Completed

Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC

Kidney Cancer | Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma

United States
Radboud University Medical Center
Dutch Cancer Society

Completed

Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250

Clear Cell Renal Cell Carcinoma

Netherlands
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

Renal Cell Cancer

Germany, Estonia, Russian Federation, Italy, United Kingdom, Netherlands, Greece, Switzerland, Finland, Lithuania, Sweden, Czech Republic
Centre Hospitalier Universitaire de Saint Etienne

Terminated

Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer (CA9CRM)

Metastatic Renal Cell Carcinoma | Metastatic Kidney Cancer

France
University of Texas Southwestern Medical Center
National Cancer Institute (NCI); Howard Hughes Medical Institute

Recruiting

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Kidney Cancer | Renal Cell Carcinoma | Urothelial Carcinoma | Hereditary Leiomyomatosis and Renal Cell Cancer | Metastatic Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | HLRCC | Clear Cell Carcinoma | Metastatic Kidney Cancer | Fumarate Hydratase Deficiency | Succinate...

United States
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited

Not yet recruiting

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Stage II Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Stanford University

Completed

Symptom Assessment With Patient Surveys

Adenocarcinoma | Squamous Cell Carcinoma | Carcinomas

United States

Clinical Trials on Adrenal Cortex Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations